Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Mallinckrodt
Harvard Business School
Baxter
Colorcon

Last Updated: February 1, 2023

Tazemetostat hydrobromide - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for tazemetostat hydrobromide and what is the scope of freedom to operate?

Tazemetostat hydrobromide is the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tazemetostat hydrobromide has three hundred and thirty-six patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for tazemetostat hydrobromide
International Patents:336
US Patents:23
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 12
Clinical Trials: 2
DailyMed Link:tazemetostat hydrobromide at DailyMed
Recent Clinical Trials for tazemetostat hydrobromide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
National Cancer Institute (NCI)Phase 1/Phase 2

See all tazemetostat hydrobromide clinical trials

US Patents and Regulatory Information for tazemetostat hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for tazemetostat hydrobromide

Country Patent Number Title Estimated Expiration
Denmark 2825161 See Plans and Pricing
Israel 252182 שיטות לטיפול בסרטן (Method for treating cancer) See Plans and Pricing
South Korea 102021642 See Plans and Pricing
Mexico 362339 FORMA DE SAL DE UN INHIBIDOR DE HISTONA METILTRANSFERASA HUMANA EZH2. (SALT FORM OF A HUMAN HI STONE METHYLTRANSF ERASE EZH2 INHIBITOR.) See Plans and Pricing
Japan 2018062535 ガンの治療方法 (METHODS OF TREATING CANCER) See Plans and Pricing
Turkey 201904660 See Plans and Pricing
Australia 2013331368 Methods of treating cancer See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Baxter
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.